Compounds > 9-aminocamptothecin
Page last updated: 2024-08-25

9-aminocamptothecin and Thrombopenia

9-aminocamptothecin has been researched along with Thrombopenia in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's4 (80.00)18.2507
2000's1 (20.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Hochster, H; Mandeli, J; Muggia, FM; Plimack, ER; Runowicz, CD; Sorich, J; Speyer, J; Wadler, S; Wallach, RC; Wright, J1
Berkery, R; Harrison, J; Kelsen, DP; Kemeny, NE; Saltz, LB; Tong, W1
Bartel, S; Bharti, A; Hurwitz, S; Levy, S; Lynch, C; Rosowsky, A; Rubin, E; Toppmeyer, D; Trites, D; Wood, V1
Beijnen, JH; Herben, VM; Hillebrand, MJ; Lieverst, J; Porro, MG; Schellens, JH; Schoemaker, NE; Schot, M; ten Bokkel Huinink, WW; van Gijn, R1
Dallaire, BK; de Jonge, MJ; Gelderblom, AH; Loos, WJ; Planting, AS; Punt, CJ; Sparreboom, A; van Beurden, V; van der Burg, ME; van Maanen, LW; Verweij, J; Wagener, DJ1

Trials

5 trial(s) available for 9-aminocamptothecin and Thrombopenia

ArticleYear
Biweekly 72-hour 9-aminocamptothecin infusion as second-line therapy for ovarian carcinoma: phase II study of the New York Gynecologic Oncology Group and the Eastern Cooperative Oncology Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-01, Volume: 22, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Camptothecin; Carcinoma; Disease Progression; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Neutropenia; Ovarian Neoplasms; Thrombocytopenia; Treatment Outcome

2004
9-Aminocamptothecin by 72-hour continuous intravenous infusion is inactive in the treatment of patients with 5-fluorouracil-refractory colorectal carcinoma.
    Cancer, 1997, Nov-01, Volume: 80, Issue:9

    Topics: Adult; Aged; Agranulocytosis; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Neutropenia; Thrombocytopenia; Treatment Outcome

1997
A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1995, Volume: 1, Issue:3

    Topics: Adult; Aged; Anemia; Antineoplastic Agents; Camptothecin; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Administration Schedule; Female; Half-Life; Humans; Infusions, Intravenous; Leukocytes, Mononuclear; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Neutropenia; Thrombocytopenia

1995
Phase I and pharmacokinetic study of a daily times 5 short intravenous infusion schedule of 9-aminocamptothecin in a colloidal dispersion formulation in patients with advanced solid tumors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Camptothecin; Colloids; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Carriers; Female; Hematopoiesis; Humans; Infusions, Intravenous; Lactones; Male; Middle Aged; Nausea; Neoplasms; Neutropenia; Thrombocytopenia

1999
Phase I and pharmacologic study of oral (PEG-1000) 9-aminocamptothecin in adult patients with solid tumors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:7

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Camptothecin; Dose-Response Relationship, Drug; Female; Humans; Least-Squares Analysis; Likelihood Functions; Male; Middle Aged; Neoplasms; Neutropenia; Pharmacokinetics; Thrombocytopenia

1999